. Preliminary results of a survey of 3,000 US citizens by the City University of New York School of Public Health suggest the drugs could"hamper the effort to get people vaccinated," said Scott Ratzan, an expert in health communication at CUNY, who led the research.
Pfizer's results followed news from Merck and partner Ridgeback Biotherapeutics on Oct. 1 that their oral antiviral drug cut hospitalization and death by half. That drug, known as molnupiravir, won conditional approval in the UK on Thursday. Both need clearance from US health regulators but could be on the market in December.
Even in the face of the highly transmissible Delta variant of the virus, the vaccines from Pfizer/BioNTech remain effective, cutting the risk of hospitalization by a combined 86.8%, according to a government study of US veterans. Choosing not to get vaccinated"would be a tragic mistake," said Albert Bourla, chief executive officer of Pfizer Inc."These are treatments. This is for the unfortunate who will get sick," Bourla told Reuters in an interview on Friday."This should not be a reason not to protect yourself and to put yourself, your household and society in danger.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: rapplerdotcom - 🏆 4. / 86 Read more »
DOH logs only 46 COVID-19 deaths due to reporting glitchMANILA, Philippines — The Department of Health (DOH) reported only 46 COVID-related deaths on Tuesday due to technical issues with its data repository. With the additional fatalities, the total deaths due to COVID-19 in the country have reached 44,567, or 1.59 percent of all the 2.8 million patients who have had the disease. ADVERTISEMENT An […]
Source: inquirerdotnet - 🏆 3. / 86 Read more »